Clinical Trial Update: HPV16 E6 TCR T Cells for Cervical Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of HPV16 E6 TCR T Cells for cervical cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• HPV16 E6 TCR T Cells

Snippet

Sponsor: TCRCure Biopharma Ltd. | Conditions: Cervical Carcinoma | Phase 1, Phase 2 | Status: TERMINATED